|
How Will Recent Safety Concerns Affect PPAR-Gamma Agonists?
Decision Resources - 6/25/2007 - 20 Pages - ID: DECR1507384
URL: http://www.marketresearch.com/product/display.asp?productid=1507384
PDF E-mail From Publisher - $1,112.50
Global Site License Fulfilled by Publisher - $2,225.00
Abstract
Introduction
The peroxisome proliferator-activated receptor (PPAR)-gamma agonist class of drugs is the fastest-growing drug class in the type 2 diabetes market. Sales of the two PPAR-gamma agonists, GlaxoSmithKline’s Avandia and Takeda’s Actos, are signifi cant drivers of type 2 diabetes market sales. However, a recent study has questioned the safety of Avandia and has triggered a debate about the use of PPAR-gamma agonists, thereby presenting commercial opportunities for new agents in the treatment of type 2 diabetes.
Questions Answered in This Spectrum Report
- PPAR-gamma agonists are among the most popular therapies in the treatment of type 2 diabetes. However, • a recent meta-analysis has highlighted the potential for cardiovascular side effects with Avandia and has affected both sales of the agent and GlaxoSmithKline’s stock price. What are the strengths and weaknesses of the Avandia study? Are the safety concerns raised by the study relevant only to Avandia or to the entire PPAR-gamma agonist class?
- The safety concerns about PPAR-gamma agonists present a commercial opportunity for new agents that offer • a unique mechanism of action, an improved safety profi le, and evidence of effi cacy. Which newly launched agents threaten to compete with the PPAR-gamma agonists for the position of preferred third-line therapy in type 2 diabetes? What advantages—and shortcomings—do these new agents have?
- Novartis is developing a drug that that promises to compete heavily with newly launched agents and further • change the landscape of the type 2 diabetes market. How will this agent differentiate itself from the currently available type 2 diabetes therapies?
Scope
- Overview of PPAR-gamma agonists: • mechanism of action, side effects, role in the treatment of type 2 diabetes.
- Avandia controversy: • safety concerns, the response to the recent meta-analysis, implications for the PPAR-gamma agonist drug class.
- Commercial opportunities for new agents: • description of agents that are newly launched or in development.
- Outlook: • how recent developments will affect the PPAR-gamma agonist drug class and the type 2 diabetes market.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- An Overview of PPAR-Gamma Agonists
- Mechanism of Action
- Side Effects of PPAR-Gamma Agonists
- PPAR-Gamma Agonists in the Treatment of Type 2 Diabetes
- PPAR-Gamma Agonists in the Type 2 Diabetes Market
- The Controversy Surrounding Avandia
- New Concerns Arise Over Avandia Use
- Response and Repercussions
- Are the Cardiovascular Risks a Class Effect?
- Do Avandia’s Safety Concerns Represent a Commercial Opportunity?
- The Incretin Pathway
- Eli Lilly/Amylin’s Byetta
- Merck’s Januvia
- Outlook for PPAR-Gamma Agonists and the Type 2 Diabetes Market
- Sidebar/Expert Commentary
- How Important Is Avandia to GlaxoSmithKline?
- Greater Transparency Needed for Clinical Trial Results
- Tables
- 1. Results from Large-Scale Trials Involving Avandia
- Figures
- 1. Mechanism of Action for PPAR-Gamma Agonists
- 2. Worldwide Sales of PPAR-Gamma Agonists, 1999-2006
- 3. Results from a Meta-Analysis of Trials Involving Avandia
- 4. Incretin Pathway
- 5. Growth of Key Drug Classes in the Type 2 Diabetes Market, 1999-2006
- 6. Comparison of Sales for Actos and Avandia, 1999-2006
More Details
Companies Mentioned in This Spectrum Report
Alkermes
Amylin
Bristol-Myers Squibb
Eli Lilly
GlaxoSmithKline
Merck
Novartis
Pfi zer
Sankyo
Sanofi -Aventis
Takeda
Warner-Lambert
|